Close Menu

NEW YORK (GenomeWeb) – In a filing with the US Securities and Exchange Commission, OpGen reported after the close of the market on Thursday that its preliminary fourth quarter revenues fell 24 percent from Q4 2015, even as full-year 2016 revenues rose 27 percent.

For the three months ended Dec. 31, 2016, OpGen expects revenues of $1.0 million, down from the $1.3 million the company reported a year ago. Full the full year, OpGen expects revenues of $4.0 million, up from $3.2 million in 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.